» Articles » PMID: 38414526

Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2024 Feb 28
PMID 38414526
Authors
Affiliations
Soon will be listed here.
Abstract

Addressing disorders related to the central nervous system (CNS) remains a complex challenge because of the presence of the blood-brain barrier (BBB), which restricts the entry of external substances into the brain tissue. Consequently, finding ways to overcome the limited therapeutic effect imposed by the BBB has become a central goal in advancing delivery systems targeted to the brain. In this context, the intranasal route has emerged as a promising solution for delivering treatments directly from the nose to the brain through the olfactory and trigeminal nerve pathways and thus, bypassing the BBB. The use of lipid-based nanoparticles, including nano/microemulsions, liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, has shown promise in enhancing the efficiency of nose-to-brain delivery. These nanoparticles facilitate drug absorption from the nasal membrane. Additionally, the in situ gel (ISG) system has gained attention owing to its ability to extend the retention time of administered formulations within the nasal cavity. When combined with lipid-based nanoparticles, the ISG system creates a synergistic effect, further enhancing the overall effectiveness of brain-targeted delivery strategies. This comprehensive review provides a thorough investigation of intranasal administration. It delves into the strengths and limitations of this specific delivery route by considering the anatomical complexities and influential factors that play a role during dosing. Furthermore, this study introduces strategic approaches for incorporating nanoparticles and ISG delivery within the framework of intranasal applications. Finally, the review provides recent information on approved products and the clinical trial status of products related to intranasal administration, along with the inclusion of quality-by-design-related insights.

Citing Articles

Investigation of paeonol in dermatological diseases: an animal study review.

Ju J, Song T, Shi J, Li J Front Pharmacol. 2024; 15:1450816.

PMID: 39588155 PMC: 11586225. DOI: 10.3389/fphar.2024.1450816.


Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals.

Akpinar Adscheid S, Tureli A, Gunday-Tureli N, Schneider M Beilstein J Nanotechnol. 2024; 15:1400-1414.

PMID: 39559726 PMC: 11572074. DOI: 10.3762/bjnano.15.113.


Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson's Disease Treatment by Intranasal Administration.

Castellani S, Iaconisi G, Tripaldi F, Porcelli V, Trapani A, Messina E Pharmaceutics. 2024; 16(8).

PMID: 39204393 PMC: 11360708. DOI: 10.3390/pharmaceutics16081048.


In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.

Ghosh A, Majie A, Karmakar V, Chatterjee K, Chakraborty S, Pandey M AAPS PharmSciTech. 2024; 25(5):96.

PMID: 38710855 DOI: 10.1208/s12249-024-02810-0.


Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport.

Gandhi S, Shastri D, Shah J, Nair A, Jacob S Pharmaceutics. 2024; 16(4).

PMID: 38675142 PMC: 11055100. DOI: 10.3390/pharmaceutics16040481.


References
1.
Wu L, Shan W, Zhang Z, Huang Y . Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties. Adv Drug Deliv Rev. 2017; 124:150-163. DOI: 10.1016/j.addr.2017.10.001. View

2.
Torres J, Pereira J, Marques-Oliveira R, Costa I, Gil-Martins E, Silva R . An In Vitro Evaluation of the Potential Neuroprotective Effects of Intranasal Lipid Nanoparticles Containing Astaxanthin Obtained from Different Sources: Comparative Studies. Pharmaceutics. 2023; 15(4). PMC: 10142572. DOI: 10.3390/pharmaceutics15041035. View

3.
Mitusova K, Peltek O, Karpov T, Muslimov A, Zyuzin M, Timin A . Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnology. 2022; 20(1):412. PMC: 9479308. DOI: 10.1186/s12951-022-01610-7. View

4.
Uppuluri C, Ravi P, Dalvi A . Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. Int J Pharm. 2021; 606:120881. DOI: 10.1016/j.ijpharm.2021.120881. View

5.
Gadhave D, Tupe S, Tagalpallewar A, Gorain B, Choudhury H, Kokare C . Nose-to-brain delivery of amisulpride-loaded lipid-based poloxamer-gellan gum nanoemulgel: In vitro and in vivo pharmacological studies. Int J Pharm. 2021; 607:121050. DOI: 10.1016/j.ijpharm.2021.121050. View